Stryker recently launched the T2 Alpha Humerus Nailing System and began a limited market release of its Mako RPS handheld robotic system for total knee procedures. These new product offerings, along with reported full-year 2025 sales of US$25.12 billion and net income of US$3.25 billion, aim to strengthen Stryker’s orthopedic and robotics ecosystem. The Mako RPS handheld system is particularly noted for potentially broadening the use cases for robotic-assisted knee procedures and reinforcing the company’s investment narrative in orthopedic robotics growth, despite ongoing risks like supply chain disruptions.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Does Stryker’s New Ortho-Robotics Launch and Results Reset the Bull Case For SYK?
Stryker recently launched the T2 Alpha Humerus Nailing System and began a limited market release of its Mako RPS handheld robotic system for total knee procedures. These new product offerings, along with reported full-year 2025 sales of US$25.12 billion and net income of US$3.25 billion, aim to strengthen Stryker’s orthopedic and robotics ecosystem. The Mako RPS handheld system is particularly noted for potentially broadening the use cases for robotic-assisted knee procedures and reinforcing the company’s investment narrative in orthopedic robotics growth, despite ongoing risks like supply chain disruptions.